We recently hosted Tjerk Opmeer from the Ministry of Economic Affairs at Leiden Bio Science Park to share insights into building a shared investment agenda for Dutch biotech.
Joined by leaders from universities, industry, and government, Esther Peters from Leiden Bio Science Park and Annetje Ottow from Leiden University opened the session by highlighting our park’s role in driving biotech innovation and economic growth.
The discussion focused on translating the national biotechnology vision into a tangible action agenda. Without a unified investment framework, there is a real risk of losing the hard-won leadership of our ecosystem. Our park’s triple helix structure, which integrates knowledge, entrepreneurship, and policy, remains essential for ensuring biotech breakthroughs reach patients and markets.
Practical insights came from the scale-ups pushing boundaries: @LeydenLabs, Meatable, and VarmX. Contributions from Nieke Campagne, Anouschka Versleijen from Luris, and Koen Venekamp from Johnson & Johnson emphasized the importance of linking early-stage R&D with commercial pathways.
By aligning interests and investments, we can keep the Netherlands at the forefront of life sciences innovation.
A new collaboration between TNO, Proefdiervrij, and pharmaceutical company Galapagos, called MechPath, is accelerating the transition to animal-free drug development. By...
The first Works Council Community meeting at Leiden Bio Science Park tackled workplace conduct and culture through honest, practical dialogue. With HR and legal experts in the room, the session marked the start of a collaborative effort to foster safer, more respectful workplaces.
EMA visited Leiden Bio Science Park to explore how regulatory tools can better support early-stage innovation. The visit connected EMA representatives with local leaders across academia, investment, and biotech development for a forward-looking exchange on speeding therapies to patients.